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ABSTRACT 97 
Background: The Healthy Activity Program (HAP), a brief behavioural intervention delivered 98 
by lay counsellors, enhanced remission over 3 months among primary care attendees with 99 
depression in peri-urban and rural settings in India. We evaluate the sustainability of the 100 
effects after treatment termination and the cost-effectiveness of the HAP over 12 months 101 
and the effects of the hypothesized mediator of activation on clinical outcomes.  102 
Methods and Findings: Primary care attenders aged 18-65 screened with moderately 103 
severe to severe depression on the Patient Health Questionnaire (PHQ-9) were randomised 104 
to either HAP plus Enhanced Usual Care (EUC) (n=247) or EUC alone (n=248), of whom 105 
95% completed assessments at 3 months and 91% at 12 months. Primary outcomes were 106 
severity on the Beck Depression Inventory version II (BDI-II) and remission on the PHQ-9.  107 
 108 
HAP participants maintained the gains they showed at the end of treatment through the 12-109 
month follow-up (difference in mean BDI-II score between 3 and 12 months=-0.34; 95% CI -110 
.2.37, 1.69; p=0.74), with lower symptom severity scores than EUC alone (adjusted mean 111 
difference in BDI-II score=-4.45, 95%CI -7.26, -1.63; p=0.002) and higher rates of remission 112 
(adjusted prevalence ratio (aPR) =1.36, 95%CI 1.15, 1.61; p<0.009). They also fared better 113 
on most secondary outcomes including recovery (aPR=1.98, 95%CI 1.29, 3.03; p=0.002), 114 
any response over time (aPR=1.45, 95%CI 1.27, 1.66), higher likelihood of reporting a 115 
minimal clinically important difference (aPR=1.42, 95%CI 1.17, 1.71; p<0.0001); and lower 116 
likelihood of reporting of suicidal behavior (aPR=0.71, 95%CI 0.51, 1.01; p=0.06). HAP plus 117 
EUC also had a marginal effect on WHO-DAS score at 12 months (aPR=-1.58, 95% CI -118 
3.33, 0.17; p=0.08); other outcomes (days unable to work, intimate partner violence toward 119 
females), did not reach statistical significance. Economic analyses indicated that HAP was 120 
dominant over EUC alone, with lower costs and better outcomes; uncertainty analysis 121 
showed that from this health system perspective there was a 95% chance of HAP being 122 
cost-effective, given a willingness to pay threshold of $16,060, equivalent to GDP per capita 123 
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in Goa, per QALY gained. Patient-reported behavioural activation levels at 3 months 124 
mediated the effects of the HAP intervention on the 12-month depression scores (b=-2.62, 125 
95% CI -3.28, -1.97;p<0.0001). Serious Adverse Events were infrequent and prevalence 126 
was similar by arm. 127 
 128 
Conclusions: HAP’s superiority over EUC at the end of treatment was largely stable over 129 
time and mediated by patient activation. HAP provides better outcomes at lower costs 130 
adopting a perspective covering publicly funded health care services and productivity 131 
impacts on patients and their families.  132 
 133 
Main limitations: We were unable to assess possible episodes of remission and relapse 134 
which may have occurred between our outcome assessment time points of 3 and 12 months 135 
post randomization. We did not account/evaluate the effect of mediators other than 136 
behavioural activation  137 
Trial registration:  ISRCTN95149997 (http://www.isrctn.com/ISRCTN95149997). 138 
 139 
AUTHOR SUMMARY 140 
 141 
Background: 142 
• Depression is the leading mental health contributor to the global burden of disease. 143 
• Access to effective treatments is low globally, but especially so in low and middle-144 
income countries (LMICs) like India where a recent national survey reported a 145 
treatment gap of 85%.  146 
• The Healthy Activity Program (HAP) is a brief psychological treatment based on the 147 
principles of behavioural activation and delivered by non-specialist providers; we 148 
have earlier reported the effectiveness of this intervention in reducing depressive 149 
symptoms and promoting remission at the end of treatment.    150 
 151 
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Why Was This Study Done? 152 
• To evaluate the sustained effectiveness and the cost-effectiveness of the HAP over 153 
12 months.   154 
• To assess whether behavioural activation reported by patients at 3 months mediated 155 
the effects of the intervention on depression at 12 months.  156 
What Did the Researchers Do and Find? 157 
• We implemented a randomised controlled trial in which 493 adult primary health care 158 
attendees with moderately severe or severe depression who were assigned to either 159 
the HAP treatment (N=245) or enhanced usual care (EUC) (N=248), and received 160 
treatment over two to three months. 161 
• HAP participants maintained the gains they showed at the end of treatment through 162 
the 12-month period, with lower symptom severity scores than EUC alone and higher 163 
rates of remission; these effects were partly mediated by increased levels of 164 
behavioural activation reported at 3 months;  165 
• HAP was highly likely to be cost-effective, and could even save money if productivity 166 
costs were taken into account. 167 
What Do These Findings Mean? 168 
• The HAP is associated with sustained effects on depression outcomes over a 12-169 
month period and represents good value for money.   170 
• The HAP is ideally suited for scaling up to reduce the treatment gap for depression. 171 
 6 
INTRODUCTION 172 
Depression is a major contributor to the global burden of disease[1], and its treatment is a 173 
priority in the global health agenda. Despite the well-documented health and economic 174 
consequences of depression[2, 3], investments in mental health are inadequate, resulting in 175 
a large treatment gap [3]. Access to treatment remains a challenge particularly in low and 176 
middle-income countries (LMICs). The recent National Mental Health Survey in India 177 
reported a treatment gap of 85% for major depression[4].  Psychological treatments (PT) are 178 
recommended as first line interventions[5], not only because they are as efficacious as 179 
pharmacological treatments, but because they also produce sustained effects after 180 
treatment termination[6]. However, there are questions about the generalizability of PTs in 181 
LMICs, where the lack of trained professionals, variations in explanatory models, and lower 182 
literacy may present structural barriers to PT [7, 8]. Some of these barriers could be 183 
overcome by the innovative use of task-sharing and there is growing evidence for the 184 
acceptability and effectiveness of contextually-sensitive PTs delivered by appropriately- 185 
trained and supervised lay health workers in primary care and community settings[9-11];  186 
however, there are very few trials which have reported on the sustained effects, cost-187 
effectiveness or mediation of the effects of these treatments.  188 
 189 
The PREMIUM (PRogram for Effective Mental health Interventions in Under-resourced 190 
health systeMs) was designed to: 1) implement a methodology for the development of 191 
scalable PTs that are culturally appropriate, affordable, and feasible for delivery by non-192 
specialist health workers; and 2) evaluate the effectiveness and cost-effectiveness of the 193 
PTs on the two leading mental health causes of the burden of disease, ie. the Counselling 194 
for Alcohol Problems program for harmful drinking[12], and the Healthy Activity Program for 195 
moderately severe to severe depression (HAP])[13, 14]. The HAP treatment is adapted from 196 
behavioural activation (BA), a treatment which has a strong theoretical and empirical 197 
evidence base across diverse contexts and patient populations[15].  The stance of BA is 198 
particularly attractive as it focusses on the link between activities and mood, whilst 199 
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emphasizing increased activation and engagement, problem solving skills, and enhanced 200 
social support. A core feature of PREMIUM was the delivery of both treatments by the same 201 
lay counsellors in routine primary care settings, as they would be used in actual clinical 202 
practice. Usual care in primary care for depression in India is, in effect, no care at all. This 203 
was confirmed in the study setting during the pilot study. This is primarily because most 204 
cases are not diagnosed and, amongst those who are, most do not receive either 205 
antidepressants or PT.   206 
 207 
Previously, we reported the favourable results of the impact of 6-8 sessions of HAP on 208 
mental health and secondary outcomes at the primary 3-month post-enrolment end-209 
point[16]. The key findings were that HAP produced significantly lower symptom severity 210 
(adjusted mean difference in the BDI-II score=-7.57, 95%CI -10.27, -4.86) and higher 211 
remission rate (adjusted prevalence ratio=1.61, 95%CI 1.34, 1.93). HAP also showed 212 
superior results on the secondary outcomes of disability, days out of work, and intimate 213 
partner physical violence in women. The incremental cost of HAP per quality adjusted life 214 
year gained was International $9,333 (95% CI 3862, 28169), with an 87% chance of being 215 
cost effective from a health systems perspective in the study setting. The question now 216 
becomes whether these effects were sustained following the end of treatment in a disorder 217 
that is highly prone to relapse and recurrence given the relatively brief duration, minimal 218 
dosage and delivery by non-specialized workers, of the HAP (‘most brief’ PTs, particularly 219 
behavioural activation-based treatments in High Income Countries, typically involve at least 220 
twice this number of sessions delivered by highly trained professionals). In addition, a 221 
meaningful sustained effect should be accompanied by a patient-defined clinically important 222 
improvement in symptoms, as well as whether the mediating factor targeted by the PT 223 
accounted its effects. In this paper, we address three novel questions: the stability of HAP’s 224 
effects on depression and other outcomes at 12 months post-enrolment; the mediation of the 225 
clinical outcomes by patient activation assessed at 3 months; and the cost-effectiveness of 226 
the intervention over 12 months.  227 
 8 
 228 
METHODS 229 
The methods are described in detail in the protocol. The trial was conducted in accordance 230 
with the protocol (S1 Protocol) (ISRCTN95149997) [17], which was approved by the Trial 231 
Steering Committee. Approval for the conduct of the trial was obtained from the Institutional 232 
Review Boards of the London School of Hygiene and Tropical Medicine, Sangath (the 233 
implementing institution in India), and the Indian Council of Medical Research. Written (or 234 
witnessed, if the participant was illiterate) informed consent was mandatory for enrolment.  235 
This study is reported as per CONSORT guidelines (S1 Checklist). 236 
 237 
Study design and participants: This was a parallel-arm individually randomized controlled 238 
trial (RCT) in ten primary health centres in Goa, a state on the west coast of India. 239 
Participants were adult primary health care (PHC) patients aged 18-65 years with a probable 240 
diagnosis of moderately severe to severe depression ascertained with the Patient Health 241 
Questionnaire (PHQ-9) score>14, a cut-point previously validated in the study setting, and 242 
who gave informed consent. Pregnant women and patients presenting with severe medical 243 
conditions requiring urgent medical attention, and those with hearing/speech difficulties were 244 
excluded. Participants were interviewed to collect data on socio-demographic factors and 245 
potential moderators of treatment outcome: gender, illness severity, duration of the illness, 246 
and expectations for treatment[18]. Sequential numbered opaque envelopes were used to 247 
randomize consenting participants in a 1:1 allocation scheme[19]. Enrolment was conducted 248 
between 28th October 2013 and 29th July 2015 and the final 12-month assessment was 249 
completed on 30th August 2016. 250 
 251 
Sample size estimation: Our sample size estimations for the 3-month primary outcomes 252 
assumed an intra-cluster correlation (ICC) between clinics of 0.04, with one counsellor per 253 
PHC at any one time, loss to follow-up of 15% over 3 months, and a 1:1 allocation ratio. 254 
Based on these we aimed to recruit 500 participants (425 in our analysis sample) to detect 255 
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the hypothesized effects: i) a standardised mean difference (effect size) of 0.42 for the 256 
primary continuous outcome of depression severity with 90% power; and ii) proportion 257 
recovered of 65% in the HAP plus EUC compared with 44% in EUC with 92% 258 
power. The high follow-up rate (attrition rate of 9%), at 12 months means that we have 90% 259 
power to detect these effect sizes at 12 months.  260 
 261 
Interventions:  Enhanced Usual Care (EUC) comprised routine consultation with the PHC 262 
physician, enhanced by providing the screening results to both PHC physician and patient, 263 
and providing copies of a contextualized version of the mhGAP guidelines to the PHC 264 
physician including when and where to refer for psychiatric care[20]. EUC was available to all 265 
trial participants. 266 
 267 
Healthy Activity Program (HAP): The HAP is a contextually adapted brief psychological 268 
treatment based on behavioural activation[13], which focused on increasing patient 269 
activation levels in pleasurable or mastery activities, and comprised the following strategies: 270 
psychoeducation, behavioral assessment, activity monitoring, activity structuring and 271 
scheduling, activation of social networks, and problem solving.  HAP was delivered in an 272 
individual format, and involved six-to-eight sessions, each lasting 30-40 minutes, with the 273 
initial sessions being at weekly intervals. The beginning phase focused on orienting to 274 
treatment, a multi-session middle phase on teaching core intervention strategies, and a late 275 
phase on reviewing gains and termination. The middle phase could be extended with up to 2 276 
additional sessions for patients who did not show sufficient improvement, allowing a 277 
maximum of 8 sessions across all phases. Patients who did not respond by the end of 278 
treatment were referred for specialist care. Details about the intervention are reported 279 
elsewhere[13] and can be accessed online (http://hap.nextgenu.org).	 A description of 280 
counsellor selection, training and supervision is published elsewhere [21] [22]. Counsellors 281 
were members of the local community, above 18 years of age, completed at least high 282 
school education, and did not have prior professional mental health training. Counsellors 283 
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underwent a three-week participatory workshop covering both PTs, followed up by an 284 
internship phase of 6 months, in which trainee counsellors delivered the treatment to eligible 285 
patients in primary health-care clinics. Eleven counsellors who met competency standards 286 
participated in the trial. They received weekly peer-led supervision in groups of four to six 287 
and individual supervision twice monthly. 288 
 289 
The same counsellor delivered the Counselling for Alcohol Problems treatment to adult 290 
males who met criteria for harmful drinking. Counsellors maintained separate clinical 291 
registers for both group of patients and reviewed individual patient records before each 292 
session. In order to ensure their treatment-specific counselling skills were maintained 293 
throughout the trial, weekly peer-led group supervision sessions were structured in ways that 294 
involved holding separate sessions for each of the two treatments. This arrangement 295 
allowed the expert supervisors for each of the two treatments to provide more focused 296 
feedback to the counsellors. 297 
 298 
Treatment fidelity was assessed at two levels: the quality with which the HAP was delivered; 299 
and the quantity of the dose of HAP administered. The quality of HAP was assessed based 300 
on a random selection of 10% of audio-recorded sessions, rated on a therapy quality 301 
scale[22], by peers and experts. The quantity of HAP delivered was assessed based on 302 
treatment completion records maintained by the counsellors. 303 
 304 
Outcomes: The two primary outcomes for the 12 month analyses were: 1) depression 305 
severity assessed by the Beck Depression Inventory version II (BDI-II) (dropping the item 306 
related to sex for cultural reasons); and 2) partial remission from depression (defined as 307 
PHQ-9 score <10). Our cut-off is in alignment with the depression treatment literature which 308 
defines remission as either the complete absence of symptoms, which is reflected by a 309 
PHQ-9 score< 5 or a partial absence of symptoms defined as PHQ-9 score<10 [23, 24]. A 310 
range of secondary outcomes included recovery from depression (PHQ9 score <5 at both 3 311 
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and 12 months); relapse (partial or full); disability; suicidal behaviour; and inter-personal 312 
violence.  313 
 314 
We estimated the Minimal Clinically Important Difference (MCID) as a patient-centred metric 315 
that captures both the magnitude of improvement and the value the patient places on that 316 
improvement[25]. We used the anchor-based approach for estimating MCID that ties change 317 
in outcome on the PHQ-9 to the patient’s subjective sense of improvement[26]; patients’ 318 
rating of perceived improvement on a ‘global rating of change’ scale[27] was used to 319 
calculate the corresponding difference in score (see S1 Table for definition of all secondary 320 
outcomes). In addition, we assessed patient-reported activation levels, using a 5-item Likert 321 
Scale (0-5) based on the Behavioural Activation for Depression Scale—Short Form[28] 322 
(BADS-SF), at 3 months to test for mediation. This variable was pre-specified as a potential 323 
mediator of the HAP on depression outcomes because patient activation levels are the 324 
primary focus of treatments for depression based on the theory of behavioral activation.  All 325 
measures were carefully selected based on their psychometric properties and contextual 326 
appropriateness. The BDI is a widely-used measure for evaluating depression in trials, and 327 
has been used in surveys in India[29]; the PHQ-9 has been validated in primary care and 328 
Konkani (widely spoken local language in trial area) version validated in Goa[30]; the WHO 329 
disability assessment schedule version 2 (WHO-DAS II) is validated for international use and 330 
used in previous trials in Goa[31, 32]; the Client Service Receipt Inventory (CSRI) has been 331 
previously used in trials in the study setting[33, 34]; the two items on intimate partner 332 
violence (IPV) were selected based on interviews used in earlier studies in Goa[35], and the 333 
BADS-SF was translated into Konkani using standardized procedures followed by 334 
piloting[13].  335 
 336 
Statistical methods: Analyses were on an intention-to-treat basis using multiple 337 
imputations (20 iterations) for missing outcome data via a data augmentation algorithm in 338 
Stata 14.0.  All models adjusted for PHC as a fixed effect to allow for within-PHC clustering 339 
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and baseline PHQ-9 scores. For continuous outcomes, intervention effects were estimated 340 
using linear regression and reported as adjusted mean differences (AMDs) and effect sizes 341 
(ESs), with 95% confidence intervals (CIs). For binary outcomes, intervention effects are 342 
reported as adjusted prevalence ratios (aPRs) estimated from logistic regression using the 343 
marginal standardisation technique for the prevalence ratios and the delta method for the 344 
CIs[36]. Sensitivity analyses included adjustment for counsellor as a random effect and 345 
complete case analyses. Repeated measures analyses were conducted to estimate the 346 
time-by-treatment interaction effect. In addition, we examined changes in mean outcome 347 
scores over time, by treatment condition. The MCID was estimated using Receiver Operator 348 
Characteristics (ROC) analysis in order to establish the minimum relative change in PHQ-9 349 
score that best differentiates those individuals who felt better from those who did not. We 350 
applied the cut-point for minimum specificity of 70% suggested by Button and 351 
colleagues[26]. Following cut-point determination, a binary outcome variable was created 352 
and intervention effects reported as adjusted prevalence ratios (aPRs) estimated from 353 
logistic regression. Results are described in terms of strength of evidence rather than 354 
statistical significance; hence we did not adjust p-values for multiple comparisons[37]. Our 355 
approach to the mediation analysis involved the Monte Carlo Method for Assessing 356 
Mediation [38, 39] which has been shown to be more rigorous than the Sobel test and as 357 
accurate as bootstrapping[40]. In the current study, we computed a 95% CI with 20,000 358 
repetitions. All regression models controlled for individual patient’s baseline PHQ-9 scores 359 
as well as any variables that were found to be significantly related to either the proposed 360 
mediator or 12-month BDI-II scores. Variance inflation factor (VIF) was conducted for each 361 
independent variable that was entered into each regression model to assess multicollinearity 362 
between independent variables, with a conservative estimate (VIF≥5).   363 
 364 
Economic evaluations were conducted from both the health care system (costs to the health 365 
system only) and the societal perspectives (health system costs plus impacts on productivity 366 
of patients and their families). Information on the use of health services, including contacts 367 
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with PHC, hospital doctor contacts and inpatient stays, medication use and diagnostic tests 368 
was collected from service users using a tailored version of the CSRI at 3 and 12 months. 369 
Unit costs for doctor contacts and inpatient stays were inflated to 2015 prices using unit 370 
costs that had previously been used for an economic evaluation in Goa[41].  Detailed 371 
information on medications and laboratory tests used, as well as costs to the public purse 372 
were recorded. Mean costs were then extrapolated to cover the full 12 months. Detailed 373 
information was also recorded on the time taken to deliver each HAP session, whether 374 
delivered at a PHC, over the telephone or at a patient’s home. Travel time and transportation 375 
costs were also recorded for home visits, including ‘no-show’ home visits. Per minute unit 376 
costs for counsellors, taking account of their training, supervision and other overheads were 377 
then attached to time to estimate the total costs of intervention delivery.  378 
 379 
Productivity costs consisted of patient time out of usual activities because of their health, as 380 
well as time costs for patients (and accompanying family members) related to the use of 381 
health services. The number of days completely out of normal role over the previous 30 days 382 
were based on patient responses to the WHO-DAS II at 3 months and 12 months. WHO-383 
DAS II data on days of activity cutback over this period were also included, with the 384 
assumption that each day of cutback would have half the value of a complete day out of role, 385 
an approach that has been adopted in High Income settings[42]. Patients reported how 386 
much time was spent attending health services using the CSRI; patients were also asked to 387 
report if they were accompanied by someone. In this case it was also assumed that one 388 
family member incurred the same level of productivity losses. We assumed that the mean of 389 
patient and family time costs at 3 months and 12 months would also apply to the rest of the 390 
year. Costs due to cutback and complete days out of role were adjusted to avoid double 391 
counting time that patients spent attending health services. All patient and family time was 392 
valued using the human capital approach making use of different daily wage rates 393 
recommended in 2015 by the Indian Labour Commission. The rate used was dependent on 394 
whether the patient was classified as an unskilled, skilled or a clerical/professional worker. 395 
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We assumed the value of days out of role for those classified unemployed were the same as 396 
those for unskilled workers. 397 
 398 
Quality Adjusted Life Year (QALY) scores were derived through transformation of WHO-DAS 399 
12 item scores as in earlier Indian trials[41]. Incremental Cost-Effectiveness Ratios (ICERs) 400 
were bootstrapped, randomly resampling pairs of outcomes and costs for intervention and 401 
comparator groups to derive 95% Cis with a distribution of mean incremental costs and 402 
effects shown on cost effectiveness planes to test the robustness of cost results. Cost-403 
effectiveness acceptability curves (CEAC) were also generated showing the likelihood that 404 
HAP would be cost-effective at different levels of willingness-to-pay. All statistical analyses 405 
were conducted using Excel 2016, SPSS 21 for the cost-effectiveness analyses; SAS, R-406 
Studio for the mediation analyses; and STATA 13/14 for all other analyses. All costs are 407 
presented in 2015 International Dollars (http://eppi.ioe.ac.uk/costconversion/). 408 
 409 
RESULTS  410 
Trial conduct: A detailed description of the conduct of the trial is provided in the primary 411 
trial paper[16]. Between October 28, 2013, and July 29, 2015, 34,306 (23%) of the 146661 412 
PHC attenders assessed met inclusion/exclusion criteria. Of these 31,888 adult PHC 413 
attenders were screened for depression using the PHQ-9 of whom 785 (2.5%) were eligible 414 
(PHQ-9 score>14) for inclusion in the trial, and 495 (63%) consented to participate and were 415 
enrolled. A total of 248 participants were randomized to EUC and 247 to HAP plus EUC. Of 416 
the latter, two were subsequently excluded (one withdrew consent and the other was 417 
erroneously enrolled in both trials) leaving a total of 245 participants treated with HAP plus 418 
EUC (Fig 1). The modal reason for non-participation was lack of time, and participants had 419 
similar baseline characteristics to non-participants. Baseline characteristics were similar by 420 
arm. 466 participants (95%) were assessed at the 3-month post-treatment endpoint and 447 421 
participants (91%) at 12-month follow-up; rates were similar between arms. A total of 438 422 
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(89%) participants had observations for both follow up time-points. In all, only 18 (3.6%) 423 
participants did not have any follow-up data. Those lost to follow-up at 12-months were 424 
younger (S2 Table), and this was similar at the 3-month post-treatment endpoint. The intra-425 
class correlation of BDI-II within PHCs was 0.02. 426 
 16 
 427 
Flow chart legend: (CAP=Counselling for Alcohol Problems. EUC=enhanced usual care. HAP=Healthy Activity Program. PHQ-428 
9=Patient Health Questionnaire 9)  429 
 430 
 431 
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 432 
Impact on clinical outcomes: There was an intervention effect on both primary outcomes 433 
at the 12-month follow-up. The mean endpoint BDI-II score was 19.73 (SD 15.53) among 434 
participants in the HAP plus EUC arm and 24.09 (SD 14.67) among participants in the EUC 435 
arm (AMD=-4.45; 95%CI -7.26, -1.63; ES=0.23, 95%CI 0.18, 0.28; p=0.002; Table 1). This 436 
main effect at 12 months was influenced by the passage of time ( p-value for time-by-437 
treatment interaction 0.04), such that participants in the EUC arm continued to improve 438 
through the 12-month follow-up (difference in mean BDI-II score between 3 and 12 439 
months=3.2; 95% CI 1.34, 5.06; p=0.001; S3 Table) while HAP plus EUC essentially 440 
retained the greater gains that it had made at the earlier assessment (difference in mean 441 
BDI-II score between 3 and 12 months=-0.34; 95% CI -.2.37, 1.69; p=0.74; S3 Table). 442 
Participants in the HAP plus EUC arm also had a higher probability of remission than those 443 
in the EUC arm (63.1% vs 48%; aPR=1.36, 95%CI 1.15, 1.61; p<0.001). As was the case for 444 
mean scores on the BDI-II, remission rates stayed relatively constant from 3 to 12 months 445 
among participants in the HAP plus EUC arm, whereas those in the EUC arm showed a 446 
slight increase by 12 months (Fig 2). Sensitivity analysis showed similar results (S4 Table). 447 
There was no evidence of moderation by gender, severity, chronicity, or patient 448 
expectancies (S5 Table).449 
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 450 
Table 1: Effects of the HAP plus EUC compared with EUC alone on primary and secondary clinical outcomes at 12 months 451 
 452 
Outcome EUC arm 
(n=248) 
HAP+EUC 
arm 
(n=245) 
1Adjusted mean difference 
(AMD), effect size (ER), 
prevalence ratio (PR), 
prevalence difference (PD) 
(95% CI) 
p-value 
Primary outcomes 
at 12 months 
    
*Mean BDI-II score 
(SD) 
24.09 (14.67) 19.73 (15.53) AMD:-4.45 (-7.26, -1.63) 
ES: 0.23 (0.18, 0.28)  
p=0.002 
**Remission: PHQ-
9<10 
no. (%) 
117 (46.98%) 155 (63.14%) PR: 1.36 (1.15, 1.61) 
PD: 16.66% (7.85%, 25.47%) 
p<0.001 
p<0.001 
Secondary 
outcomes at 12 
months 
    
***Recovery: PHQ-
9<5 at 3 & 12m  
no. (%) 
 33 (13.27%) 64 (26.10%) PR: 1.98 (1.29, 3.03) 
PD: 12.96% (5.31%, 20.61%) 
p=0.002 
p=0.001 
***Full relapse: 
PHQ-9 score 15-27 
no. (%) 
12 (4.92%) 21 (8.78%) PR: 1.79 (0.87, 3.69) p=0.14 
***Partial relapse: 
PHQ-9 score 10-14 
no. (%) 
7 (2.70%) 21 (8.60%) PR: 3.19 (1.27, 7.88) p=0.01 
***Mean PHQ-9 
score (SD) 
10.46 
(7.54) 
8.16 
(6.96) 
AMD: -2.36 (-3.70, -1.02) 
ES: 0.37 (0.32, 0.42) 
p<0.001 
Any response over 
12 months no. (%) 
266 (53.97%) 383 (77.65%) PR: 1.45 (1.27, 1.66) 
 
p<0.0001 
#Suicidal behaviour  66 (26.55%) 47 (19.10%) PR: 0.71 (0.51, 1.01) p=0.06 
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Outcome EUC arm 
(n=248) 
HAP+EUC 
arm 
(n=245) 
1Adjusted mean difference 
(AMD), effect size (ER), 
prevalence ratio (PR), 
prevalence difference (PD) 
(95% CI) 
p-value 
(Suicide thoughts) 
– no. (%) 
$MCID (% 
reduction in 
baseline PHQ-9 
score) 
102 (41.25%) 142 (58.10%) PR: 1.42 (1.17, 1.71)  
PD: 17.08% (7.89%, 26.26%)  
p<0.0001 
p<0.0001 
1 Adjusted for PHC as a fixed effect and PHQ-9 baseline score 453 
* Sensitivity analysis (point estimate: AMD): Random effects =-4.41(-7.21, -1.61); complete case = -4.57 (-7.34, -1.81); excluding unmasked (3.7%)=-4.40 (-454 
7.29, -1.51) 455 
** Sensitivity analysis (point estimate: PR): complete case=1.36 (1.14, 1.61) 456 
***Not previously specified in trials protocol but specified in published analysis plan  457 
#Suicidal thoughts over the past two weeks were assessed through the relevant PHQ-9 item while suicide attempts were assessed over the 3-month period 458 
leading up to the 12-month outcome follow up assessment. Attempts not included as numbers very small (only 2 patients (1 in each arm) reported suicide 459 
attempt over the period). ## Among married participants.  460 
$Minimal Clinically Important Difference: estimated based on relative difference in baseline and outcome score, and how this compares with overall subjective 461 
global rating of ‘feeling better’ at the end of the trial. The optimal cut-off in relative change in score with maximum specificity (>70%) is 55462 
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 463 
 464 
 465 
Figure legend: EUC arm: Enhanced Usual Care arm 466 
HAP arm: Healthy Activity Programme arm 467 
 468 
Participants in the HAP plus EUC arm had a higher probability of remission and recovery 469 
compared to those in the EUC arm (Table 1). While participants in the HAP plus EUC arm 470 
who had remitted at 3 months had a higher probability of partial relapse at 12 months 471 
compared to those in the EUC arm, the proportion with full relapse was similar between 472 
arms (Table 1).  Participants in the HAP plus EUC arm also had a higher probability of any 473 
response over the 12 months (Table 1, Fig 3). More participants remitted in HAP plus EUC 474 
in the short-term compared to EUC alone, but as expected were more likely to relapse 475 
following treatment termination than patients who remitted in EUC alone (Fig 3). Participants 476 
in the HAP plus EUC arm had marginally lower prevalence of suicidal behavior (mainly 477 
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suicide thoughts as there were only two attempts) at 12 months. Our analysis on what 478 
constitutes a MCID, revealed a relative score change of 55% from baseline. Based on this 479 
score change, HAP plus EUC was superior to EUC at 12 months (aPR=1.42, 95% CI 1.17, 480 
1.71; p<0.0001, Table 1).481 
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 482 
Figure 3: Clinical trajectories in cases with 3 and 12-month outcome data 483 
(n=438) 484 
 485 
 486 
Figure legend: EUC arm: Enhanced Usual Care arm 487 
HAP arm: Healthy Activity Programme arm 488 
  489 
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Impact on other outcomes and mediation analyses: HAP plus EUC also had a marginal 490 
effect on WHO-DAS score at 12 months (aPR=-1.58, 95% CI -3.33, 0.17; p=0.08); other 491 
outcomes (days unable to work, intimate partner violence toward females), did not reach 492 
statistical significance (Table 2).  The prevalence of SAEs (HAP plus EUC=23; EUC=23) 493 
and proportion of participants prescribed antidepressant medications (HAP plus EUC=7; 494 
EUC=11) did not differ between the treatments (S6 Table). Our assessment of mediation 495 
demonstrated that patient-reported behavioural activation levels at 3-months partially 496 
mediated the superiority of HAP plus EUC relative to EUC in terms of reduced depression 497 
severity at 12-months (Beta coefficient=-2.62, 95% CI -3.28, -1.97; p<0.0001; Fig 4, also S7 498 
Table). Patient-reported behavioural activation could account for 58% of the total effect of 499 
HAP plus EUC. None of the models evidenced multi-collinearity between the independent 500 
variables (VIF<5).  501 
 502 
Of the 245 participants in the HAP group (receiving a total of 1181 sessions), 169 (69%) had 503 
a planned discharge, of whom seven (4%) were referred for specialist care. The median 504 
number of sessions was six (IQR five to seven). Patients with an unplanned discharge were 505 
likely to stop attending early (median one session [IQR none to two]) 506 
 507 
  508 
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Table 2: Effect of HAP plus EUC compared with EUC alone on disability and 509 
intimate partner violence at 12 months  510 
 511 
Outcome EUC arm 
(n=248) 
HAP+EUC 
arm 
(n=245) 
1Adjusted mean 
difference (AMD), 
effect size (ER), 
prevalence ratio (PR), 
(95% CI) 
p-value 
Mean disability 
score  (SD) 
10.89 (9.22) 9.38 (9.61) AMD: -1.58 (-3.33, 0.17) 
ES: 0.03 (-0.03, 0.8) 
p=0.08 
Mean days unable 
to work (SD) 
6.05 (8.81) 4.81 (8.24) AMD: -1.29 (-2.89, 0.31) 
ES: 0.09 (0.04, 0.15) 
p=0.12 
Intimate partner 
physical violence## 
– females no. (%) 
20/118 
(16.57%) 
11/109 
(9.86%) 
PR: 0.60 (0.29, 1.22) p=0.16 
Intimate partner 
psychological/emoti
onal violence## – 
females no. (%) 
40/118 
(33.86%) 
28/109 
(26.10%) 
PR: 0.75 (0.50, 1.13) p=0.17 
Intimate partner 
psychological/emoti
onal violence## – 
males no. (%) 
12/40 
(28.75%) 
7/34 
(19.23%) 
PR: 0.82 (0.36, 1.84) p=0.62 
1 Adjusted for PHC as a fixed effect and PHQ-9 baseline score 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
  534 
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 535 
 536 
 537 
Figure legend:  538 
Beta coefficient 539 
a’: a-path (HAP-mediator) 540 
b:  b-path (mediator-outcome) 541 
c: direct effect (HAP-outcome) 542 
axb: indirect effect 543 
 544 
 545 
  546 
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Costs and cost effectiveness:  While health system costs had been significantly higher at 547 
3 months follow up due to the cost of providing HAP, by 12 months these costs were offset 548 
by reductions in the use of health services through month 12 and there was no statistically 549 
significant difference in health system costs between the two arms (S8 Table).  From a wider 550 
societal perspective, which combines impacts on the health system with impacts on 551 
productivity costs, the HAP plus EUC group had significantly lower costs at 12 months 552 
(mean difference -$154.93, 95% CI -$305.51, -$4.35; p=0.044), this was due to lower costs 553 
of days out of work and work cutback (mean difference -$146.28 (-$218.08, -$74.47 554 
p=0.000). While there is still a gain in mean QALYs per person at 12 months, this difference 555 
was not quite statistically significant (mean difference 0.011, 95% CI 0.006, -0.002 p=0.092). 556 
Table 3 provides an assessment of cost effectiveness showing ICERs. It indicates that the 557 
incremental cost per QALY gained is -$1,721; thus, the HAP is associated with both lower 558 
costs and better outcomes than EUC alone. To test the robustness of the ICER results, two 559 
cost effectiveness analysis planes were generated using 1000 randomly resampled pairs of 560 
costs and QALY outcomes from both health system and societal perspectives to generate 561 
further incremental cost per QALY gained values (Fig 5).  This can help policymakers by 562 
showing the likelihood that any intervention will be cost effective or even cost saving. Figure 563 
5 (A) indicates that HAP plus EUC has a 58% chance of being cost saving from a health 564 
system perspective, i.e. 58% of the 1000 pairs of costs and QALYs are in the south-east 565 
quadrant, which indicates that the intervention (in this case HAP plus EUC) has both lower 566 
costs and better QALY outcomes than EUC, while a further 39% of the 1000 pairs of cost 567 
and QALYs fall in the north-east quadrant, where HAP plus EUC is more effective but more 568 
expensive than EUC.  Nearly all of the observations in this quadrant were still below the cost 569 
effectiveness threshold used in the analysis (shown by the red line) of GDP per capita per 570 
additional QALY gained, a threshold which has been applied in economic evaluations in 571 
LMIC[43]. This threshold in the state of Goa expressed in international dollars in 2015 was 572 
$16 060[44].  Overall this means that the case for investment is very strong with a 95% 573 
likelihood that investment in the intervention will be cost effective, including a 58% chance 574 
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that it will be cost saving. Similarly, in Figure 5 (B) when costs also include a conservative 575 
estimate of productivity losses to patients and families, 98% of the pairs of costs and QALYs 576 
fall in the south-east quadrant, where HAP plus EUC is cost saving with lower costs and 577 
better outcomes compared to EUC.  As Table 3 shows, if the same approach is used to look 578 
at costs per additional remission achieved compared to EUC from a health system 579 
perspective, HAP plus EUC would be considered a highly worthwhile investment (S2 Fig) 580 
with a 90% chance of being cost effective, including a 59% chance of being cost saving.  581 
 582 
Table 3: Cost-effectiveness analyses from health system and societal 583 
perspectives (2015 International Dollars) 584 
 
Health system 
perspective 
Likelihood 
ICER cost 
saving (CS) 
and cost 
effective (CE) 
Societal 
perspective 
Likelihood cost 
saving (CS) and 
cost effective (CE) 
Cost per 
QALY gained 
at 12 months 
(95% CI)*   
-1721 
(-23,966, 18,158) 
CS: 58% 
 
CE: 95%  
-14,438  
(-81,359, 13,966) 
CS: 98% 
 
CE: 99% 
Cost per 
remission at 
12 months 
(95% CI)** 
-149  
(-1,304, 988) 
CS: 59% 
 
CE: 90% 
-1,250  
(-3,869, -186) 
CS: 99% 
 
CE: 100% 
 585 
*Assumes willingness to pay threshold equivalent to GDP per capita in Goa ($16,060) 586 
**Assumes willingness to pay threshold equivalent to one month’s wages for unskilled manual worker 587 
in Goa ($415)588 
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   589 
Figure 5: Cost effectiveness planes: HAP plus EUC compared to EUC 
A (Health System Perspective)       B (Societal Perspective) 
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 590 
DISCUSSION 591 
We report on the sustained effects, the cost-effectiveness, and the role of behavioural 592 
activation in mediating the effectiveness of the Healthy Activity Program, a brief 593 
psychological treatment delivered by lay counsellors to primary care attenders with 594 
moderately severe to severe depression in a randomized controlled trial in India. We have 595 
two main findings.  596 
 597 
First, the effects of the HAP on acute depression observed shortly after the end of treatment 598 
(3 months) were largely sustained through the 12-month follow-up. This is striking because 599 
depression tends to return after treatment termination among recently remitted patients, one 600 
of the reasons why physicians are encouraged to keep patients on active medications for at 601 
least four months following initial remission[24]. What makes that less surprising is that HAP 602 
is adapted from behavioral activation and that approach was found to reduce risk for 603 
subsequent relapse by more than half, relative to prior medications in the one study in which 604 
they have been compared[45]. Patients who remitted on HAP in the short-term were more 605 
likely to relapse following treatment termination than patients who remitted in EUC, but that 606 
is to be expected since more patients remitted on HAP than in EUC and it is plausible that 607 
those additional remitters were tougher patients at higher risk (Fig 3). That being said, HAP’s 608 
effects were relatively stable over time (i.e. depression severity scores did not change) and 609 
absolute relapse rates were lower than those observed for behavioral activation in the 610 
largest comparable trials[45]. In a disorder that is prone to relapse, that augers well for the 611 
possibility that HAP might have an enduring effect. 612 
 613 
Our second major finding was that HAP essentially pays for itself and more. It cost $65.66 614 
per patient to provide HAP but those extra treatment costs were completely offset by 615 
reductions in other health care expenses across the course of a year so that health care 616 
costs between the two trial arms were no longer significantly different at 12 months (they 617 
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had been significantly higher in the 3-month analysis[16]). Moreover, there was a very high 618 
95% probability of HAP plus EUC being cost effective from a health system perspective, 619 
including a 58% probability that it would be cost saving.   What our data suggest therefore is 620 
that the initial additional costs of providing HAP will be at least budget neutral from a health 621 
system perspective, while improving clinical outcomes. 622 
 623 
When we factor in societal costs in terms of productivity, the economic benefits of HAP 624 
become even more evident. Poor mental health has been associated with significantly lower 625 
rates of participation in employment in Low, Middle and High-Income Countries, including in 626 
India, where severe mental illness has been associated with a 40% reduction in individual 627 
earnings[46]. Poor mental health also reduces the opportunity to contribute in other ways to 628 
the economy, such as household activities, because of time of usual activity; it also 629 
increases the use of informal care and support from families. Our analysis indicates that we 630 
also make major gains in terms of productivity that have real implications for the individuals 631 
involved and for the larger society in which they are embedded. The United Kingdom has 632 
committed over £700 million pounds to train therapists to deliver empirically-supported 633 
treatments like behavioral activation on the premise that doing so would be good for the 634 
economy[47]. Our data suggest that this assumption might well hold for this Indian setting 635 
despite the substantial structural differences which mean that the interventions and their 636 
contexts are not directly comparable. 637 
 638 
Additionally, we observed that patients who received HAP reported feeling better 639 
subjectively at 12 months post-enrolment than patients who received EUC alone. HAP 640 
patients not only were better in terms of reported symptoms but they had the subjective 641 
sense that they were better in ways that actually mattered to them. This adds a patient-642 
centered outcome to our main effectiveness results. At the same time, our mediation 643 
analysis suggested that patient-reported levels of behavioral activation at 3 months 644 
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mediated the effects of HAP in reducing depression severity at 12-months. This suggests 645 
that behavioural activation may underlie HAP’s sustained effects and, thus, adds to existing 646 
evidence suggesting that patient-reported activation levels mediate response to behavioral 647 
activation therapy as specified by theory[48, 49]. 648 
 649 
Our effects were modest and about a third of patients treated with HAP remained at least 650 
moderately symptomatic. That being said, HAP was a very brief treatment by western 651 
standards (only 6-8 sessions) and was delivered by lay counsellors; most efficacy trials 652 
provide two-to-three times that many sessions delivered by highly trained professionals[50, 653 
51]. Treatment differences did narrow over time from the 3-month post-treatment 654 
assessment to the 12-month follow-up but that was largely a function of continued 655 
improvement in the EUC condition (likely due to spontaneous remission) and not any loss of 656 
efficacy for HAP over time (within condition changes were not significant). Even the elevated 657 
relapse rate for HAP relative to EUC was limited to partial relapse (requiring a change of as 658 
little as a point to rise to 10 or above on the PHQ-9); there were no differences with respect 659 
to full relapse (scores of 15 or above). Notwithstanding these notable benefits, it is clear that 660 
HAP is not sufficient as a stand-alone treatment for depression for a sizeable minority of 661 
patients in primary care. Whether its dosage or duration needs to be extended or 662 
nonresponders switched or augmented with another treatment (like medications) remains to 663 
be determined.   664 
 665 
We acknowledge limitations of this study design. First, from a methodological perspective, 666 
we only had two assessment time points at 3 months and 12 months, thus precluding 667 
detection of possible episodes of remission and relapse between these two time points[52]. 668 
Second, we continue to observe a pattern of discordance between our two primary outcome 669 
measures similar to what we found in our 3-month outcome assessments; patients at 12 670 
months were in the low end of the moderate range of severity on the BDI-II, but the same 671 
patients were indicated as having mild residual symptoms on the PHQ-9. This suggests 672 
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potential cross-cultural challenges with the use of the BDI-II, which we are currently 673 
investigating in a separate report. Third, and according to the sequential ignorability 674 
assumption[53], there is a chance that there may be other confounders that we did not 675 
assess that may explain the relation between the proposed mediator (in this case, patient 676 
activation) and depression outcomes. While our proposed mediator was selected apriori and 677 
based on the conceptual theory of behavioural activation, future studies considering 678 
additional mediators through, for example, comprehensive structural equation models are 679 
required to verify our findings and address the sequential ignorability assumption[54]. Lastly, 680 
we did not apply diagnostic criteria in recruiting patients at baseline or in our definition of 681 
outcome, but we note that the PHQ-9 is widely used to define case-level morbidity in trials 682 
and, importantly, we used locally validated cutoffs in this study[30].  683 
 684 
Clinical implications and conclusions 685 
In conclusion, our findings are consistent with the small but growing body of evidence 686 
suggesting an enduring effect for behavioural activation or more cognitive behavioural 687 
approaches [45, 51, 55]. HAP is unique in that, despite its brevity and delivery by a lay 688 
counsellor, it is able to sustain short-term gains in a LMIC primary care setting. In addition, 689 
HAP is only one of two[56] brief behavioural activation theory-based PT delivered by lay 690 
counsellors in primary care settings yet evaluated. The low levels of antidepressant 691 
medication (ADM) noted in our study, even after the diagnosis was conveyed to the primary 692 
care physician confirms that the effect of HAP could hot have been confounded by ADM 693 
use, and further supports the applicability of the HAP treatment in this treatment naïve 694 
population. The ecological validity of the trial was enhanced by the fact that the lay 695 
counsellors had no prior professional mental health training (as would be the case in most 696 
real-world settings) and that they were concurrently delivering a completely different PT for 697 
harmful drinking (as would be the case in actual practice) (Nadkarni et al, companion 698 
paper[57]). The importance of establishing sustained effects of treatments cannot be 699 
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overemphasized given depression tends to relapse or recur. We have demonstrated that 700 
brief psychological treatments like HAP and the Counselling for Alcohol Problems (CAP) 701 
program delivered by non-specialist mental health workers in routine primary care can have 702 
sustained clinical effects and are good value for the money.  Such treatments are ideal for 703 
scaling up and future research should focus on: 1) employing SMART designs to assess 704 
how different interventions can be applied in sequence to achieve higher rates of remission 705 
and recovery[58]; and 2) examining the potential roles of multiple mediators within 706 
randomised trial designs so that the effectiveness of treatments can be enhanced through a 707 
focus on these mediators.  708 
 709 
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Supplementary tables and figures 899 
 900 
S1 Table: Secondary outcomes at 12 months. 901 
Secondary outcome Measure of outcome 
Recovery from depression PHQ-9 score <5 at both 3 and 12 months 
Full relapse PHQ-9 score >14 at 12 months amongst patients 
with at least partial remission at 3 months. 
Partial relapse  PHQ-9 score 10 to 14 at 12 months amongst 
patients with at least partial remission at 3 months. 
Disability  Mean disability score on the WHO disability 
assessment schedule version 2 (WHO-DAS II[59]) 
Total days unable to work Mean total days unable to work in the previous 
month on the WHO-DAS II. 
Suicidal behaviour Proportion reporting suicide thoughts in the last 
two weeks on the PHQ-9; proportion reporting any 
suicide attempts in the last 3 months 
Intimate partner violence Proportion reporting experience of intimate partner 
violence (physical/psychological/emotional) over 
the past 3 months. 
Minimal Clinically Important Difference 
(MCID) 
Change in PHQ-9 outcome score from baseline 
compared with the corresponding score on 
patient’s subjective sense of improvement. 
Any response over 12 months PHQ-9 score <10 at either of the 3- and 12-month 
outcome assessment points (added post-hoc but 
before analysing the data). 
Resource impacts for the health 
system 
Estimates of cost-effectiveness/cost-saving using 
detailed electronic records on HAP delivery, as 
well as other use of primary and secondary care 
services collected from patients using the Client 
Service Receipt Inventory[60]. 
 902 
S2 Table: Comparison of participants who were followed up and those lost to follow 903 
up at 3 and 12 months 904 
 
Lost before 
3-month 
evaluation 
N=27 
(5.5%) 
Completed 
3-month 
outcome 
evaluation 
N=466 
(94.5%) 
Lost before 
12-month 
evaluation 
N=46 
(9.3%) 
Completed 12-
month 
outcome 
evaluation 
N=447 (90.7%) 
p-value (12-
month 
follow up) 
*Age (years) (mean [SD]) 36.2 (11.6) 42.9 (12.0) 35 (11.8) 43 (11.8) p<0.001 
Gender (Female) (n [%]) 23    (85%) 356  (76%) 35 (76%) 344 (77%) p=0.86 
Marital status (n [%]) 
Married 
Single 
Separated/Divorced 
Widowed 
 
16    (59.3%) 
8      (29.6%) 
1      (3.7%) 
2      (7.4%) 
 
321  (68.9%) 
49    (10.5%) 
3      (0.6%) 
93    (20.0%) 
 
33 (71.7%) 
11 (23.9%) 
0   (0.0%) 
2   (4.4%) 
 
304 (68.0%) 
46   (10.3%) 
4     (0.9%) 
93   (20.8%) 
 
 
p=0.004 
Education status (n [%]) 
None 
Primary 
Secondary 
Higher Secondary 
 
6      (22%) 
13    (48%) 
5      (19%) 
2      (7%) 
 
124  (27%) 
236  (50%) 
73    (16%) 
22    (5%) 
 
7 (15%) 
23 (50%) 
6 (13%) 
6 (13%) 
 
123 (28%) 
226 (51%) 
72 (16%) 
18 (4%) 
 
p=0.004 
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Lost before 
3-month 
evaluation 
N=27 
(5.5%) 
Completed 
3-month 
outcome 
evaluation 
N=466 
(94.5%) 
Lost before 
12-month 
evaluation 
N=46 
(9.3%) 
Completed 12-
month 
outcome 
evaluation 
N=447 (90.7%) 
p-value (12-
month 
follow up) 
Graduate/above 1      (4%) 11    (2%) 4 (9%) 8   (2%) 
Occupation (n [%]) 
Unemployed 
Unskilled manual labour 
Skilled manual labour 
Clerical & professional 
 
14    (52%) 
12    (41%) 
0      (0%) 
1      (3%) 
 
278 (60%) 
162 (35%) 
7     (2%) 
19   (4%) 
 
22 (48%) 
18 (39%) 
0 (0%) 
6 (13%) 
 
270 (60%) 
156 (35%) 
7 (2%) 
14 (3%) 
 
p=0.02 
Patient’s expectation of 
counselling (n [%]) 
Not useful 
A little/somewhat useful 
Moderately useful 
Very useful 
 
 
0      (0%) 
8      (31%) 
8      (28%) 
11    (38%) 
 
 
1     (0.2%) 
218 (47%) 
108 (23%) 
139 (30%) 
 
 
0 (0%) 
14 (30%) 
13 (28%) 
19 (41%) 
 
 
1 (0.2%) 
212 (47%) 
103 (23%) 
131 (29%) 
 
 
p=0.13 
Chronicity of symptoms-
wks (median [IQR]) 
 
4 (4-15) 
 
12 (4-48) 
 
9 (4-24) 
 
12 (4-48) 
 
p=0.22 
Median PHQ score 
(median [IQR]) 
 
17   (15-18) 
 
17   (16-20) 
 
18 (15-19) 
 
17 (16-20) 
 
p=0.55 
Mean PHQ-score (SD) 17.3 (1.9) 18.0 (2.8) 17.6 (2.4) 17.9 (2.7) p=0.43 
PHQ category (n [%]) 
Score 15-19 (Mod. severe) 
Score 20-27 (severe) 
 
24    (90%) 
3      (10%) 
 
348  (75%) 
118  (25%) 
 
37 (80%) 
9 (20%) 
 
335 (75%) 
112 (25%) 
 
p=0.48 
Trial Arm 
EUC 
HAP+EUC 
 
12 (44%) 
15 (56%) 
 
236(49%) 
230 (51%) 
 
19 (41%) 
27 (59%) 
 
229 (51%) 
218 (49%) 
 
p=0.22 
 905 
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S3 Table: Results of t-test and descriptive statistics for change in mean primary outcome score between 3 and 12 month endpoints 906 
by trial arm (complete case N=438) 907 
Trial arm Endpoint 95% CI for Mean Difference t df p-value 
 3 months Mean (SD) 12 months Mean (SD)     
BDI-II  
EUC 27.66 (13.27) 24.46 (14.66) 3.2 (1.34, 5.06) 3.39 224 p=0.001 
HAP+EUC 19.64 (15.45) 19.97 (15.59) -0.34 (-.2.37, 1.69) -0.33 212 p=0.74 
 908 
S4 Table: Effect of the HAP treatment plus EUC on scores for depression symptoms, disability, suicide behavior, and intimate 909 
partner violence over 9 months, based on complete case and random effects 910 
SENSITIVITY 
ANALYSIS 
EUC arm 
(n=229) 
HAP+EUC arm 
(n=218) 
1Adjusted mean difference 
(AMD), effect size (ER), 
prevalence ratio (PR), prevalence 
difference (PD) (95% CI) 
p-value 
PRIMARY 
OUTCOMES  
 
Complete case  
Mean BDI-II score 
(SD) 
24.37 
(14.65) 
19.83 (15.56) AMD: -4.57 (-7.34, -1.81) 
ES: 0.30 (0.11-0.48) 
p=0.001 
Remission: PHQ-
9<10- no. (%) 
107 
(46.72%) 
137 (62.84%) PR: 1.36 (1.14, 1.61) p=0.0004 
Random effects  
Complete case 
adjusting for 
counsellor/PHC as 
random effect (BDI-II 
score) 
24.37 
(14.65) 
19.83 (15.56) AMD: -4.57(-7.34, -1.81) 
ES: 0.30 (0.11, 0.48) 
p=0.001 
Multiple imputation 
adjusting for 
counsellor/PHC as 
24.09 
(14.67) 
19.73 (15.53) AMD: -4.41(-7.21, -1.61) 
ES: 0.23 (0.17, 0.28) 
p=0.002 
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SENSITIVITY 
ANALYSIS 
EUC arm 
(n=229) 
HAP+EUC arm 
(n=218) 
1Adjusted mean difference 
(AMD), effect size (ER), 
prevalence ratio (PR), prevalence 
difference (PD) (95% CI) 
p-value 
random effect (BDI-II 
score) 
SECONDARY 
OUTCOMES 
 
Complete case  
Recovery: PHQ-9<5 
at 3 and 12 months- 
no. (%) 
 48 
(20.96%) 
66 (30.28%) PR: 1.44 (1.05, 1.97) 
PD: 9.27% (1.43%, 17.11%) 
p=0.022 
p=0.021 
***Full relapse: PHQ-
9 score>14- 
no. (%) 
11 (4.80%) 19 (8.72%) PR: 1.81 (0.88, 3.69) p=0.11 
***Partial relapse: 
PHQ-9 score>9<15- 
no. (%) 
2 (2.62%) 18 (8.26) PR: 3.15 (1.27, 7.79) p=0.013 
***Mean PHQ-9 
score (SD) 
10.57 
(7.58)  
8.19  
(6.91) 
AMD: -2.41 (-3.72, -1.09) 
ES: 0.33 (0.14, 0.51) 
p<0.0001 
Any response over 
12 months no. (%) 
129/240 
(53.75) 
182/235  
(77.45) 
PR: 1.44 (1.26, 1.26) p<0.0001 
Mean disability score  
(SD) 
10.89 
(9.22) 
9.38  
(9.61) 
AMD: -1.58 (-3.33, 0.17) 
ES: 0.03 (-0.03, 0.8) 
p=0.08 
Mean days unable to 
work (SD) 
6.05  
(8.81) 
4.81  
(8.24) 
AMD: -1.29 (-2.89, 0.31) 
ES: 0.09 (0.04, 0.15) 
p=0.12 
Suicidal behaviour 
(Suicide thoughts) – 
no. (%)# 
 61/229 
(26.64) 
 41/218  
(18.81) 
PR: 0.70 (0.49, 0.99) p=0.046 
Intimate partner 
physical violence##– 
females no. (%) 
19/116 
(16.38) 
10/103  
(9.71) 
PR: 0.59 (0.29, 1.21) p=0.149 
Intimate partner 
psychological/emotio
nal violence## – 
39/116 
(33.62) 
27/103  
(26.21) 
PR: 0.75 (0.49, 1.13) p=0.173 
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SENSITIVITY 
ANALYSIS 
EUC arm 
(n=229) 
HAP+EUC arm 
(n=218) 
1Adjusted mean difference 
(AMD), effect size (ER), 
prevalence ratio (PR), prevalence 
difference (PD) (95% CI) 
p-value 
females no. (%) 
Intimate partner 
psychological/emotio
nal violence## – 
males no. (%) 
11/39 
(28.21) 
6/32  
(18.75) 
PR: 0.36 (0.37, 1.94) p=0.711 
$MCID (% reduction 
in baseline PHQ-9 
score) 
93 (40.61) 125 (57.60) PR: 1.21 (1.05, 1.39) p=0.009 
Random effects   
Complete case 
adjusting for 
counsellor as random 
effect (PHQ-9 score) 
10.57 
(7.58) 
8.19 
(6.91) 
AMD: -2.41 (-3.72, -1.09) 
ES: 0.33 (0.14, 0.51) 
p<0.0001 
Multiple imputation 
adjusting for 
counsellor as random 
effect (PHQ-9 score) 
10.46 
(7.54) 
8.16 
(6.96) 
AMD: -2.34 (-3.67, -1.00) 
ES: 0.37 (0.31, 0.42) 
p<0.0001 
Complete case 
adjusting for 
counsellor as random 
effect (Mean 
disability score) 
11.05 
(9.22) 
9.43  
(9.62) 
AMD: -1.64  (-3.34, 0.05) 
ES: 0.17 (-0.01, 0.36) 
p=0.057 
Multiple imputation 
adjusting for 
counsellor as random 
effect (Mean 
disability score)   
10.89 
(9.22) 
9.38  
(9.61) 
AMD: -1.55  (-3.29, 0.19) 
ES: 0.03 (-0.03, 0.08) 
p=0.082 
Complete case 
adjusting for 
counsellor as random 
effect (Mean days 
6.14  
(8.83) 
4.81  
(8.21) 
AMD: -1.31  (-2.86, 0.23) 
ES: 0.16 (-0.03, 0.34) 
p=0.096 
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SENSITIVITY 
ANALYSIS 
EUC arm 
(n=229) 
HAP+EUC arm 
(n=218) 
1Adjusted mean difference 
(AMD), effect size (ER), 
prevalence ratio (PR), prevalence 
difference (PD) (95% CI) 
p-value 
unable to work) 
Multiple imputation 
adjusting for 
counsellor as random 
effect (Mean days 
unable to work) 
6.05 (8.81) 4.81 (8.24) AMD: -1.26  (-2.86, 0.33) 
ES: 0.09 (0.04, 0.15) 
p=0.121 
  911 
Note: 912 
1 Adjusted for PHC as a fixed effect and PHQ-9 baseline score 913 
***Not previously specified in trials protocol but specified in published analysis plan. #Suicidal thoughts over the past two weeks were assessed through the 914 
relevant PHQ-9 item while suicide attempts were assessed over the 3-month period leading up to the 12 month outcome follow up assessment. Attempts not 915 
included as numbers very small (only 2 patients (1 in each arm) reported suicide attempt over the period). ## Among married participants. $Minimal Clinically 916 
Important Difference: estimated based on relative difference in baseline and outcome score, and how this compares with overall subjective global rating of 917 
‘feeling better’ at the end of the trial. The optimal cut-off in relative change in score with maximum specificity (>70%) is 55%. 918 
 919 
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S5 Table: Interaction effect of baseline depression severity, gender, chronicity of 920 
depression, and expectations of treatment, on the effect of HAP plus EUC on scores 921 
for depression symptoms (BDI-II outcome) 922 
1 Adjusted for PHC as a fixed effect and PHQ-9 baseline score 923 
Analysis EUC arm 
(n=248) 
HAP+EUC 
arm 
(n=245) 
1Adjusted mean 
difference (95% CI) 
p-value  
Baseline severity  p-effect modification = 0.227 
Moderate 22.77 [14.28] 19.69 [15.72] -3.54 (-6.85, -0.22) p=0.037 
Severe 28.59 [15.17] 19.42 [15.04] -8.41 (-14.29, -2.53) p=0.006 
  
Gender  p-effect modification= 0.857 
Males (mean 
score[SD]) 
24.28 [14.84] 20.07 [13.60] -3.64 (-9.44, 2.17) p=0.216 
Females (mean 
score[SD]) 
24.24 [14.69] 19.62 [16.15] -4.90 (-8.26, -1.55) p=0.004 
  
Chronicity   p-effect modification=0.181 
<12 weeks 21.76 [14.78] 18.68 [15.28] -2.89 (-6.87, 1.10) p=0.155 
>=12 weeks 27.59 [14.04] 20.59 [15.74] -6.86 (-10.86, -2.86) p=0.001 
  
Expectation  p-effect modification=0.629 
Not or somewhat 
useful 
23.70 [13.96] 19.69 [15.28] -4.15 (-8.11, -0.19); p=0.040 
Moderate or very 
useful 
24.38 [15.58] 20.00 [16.04] -5.32 (-9.36, -1.29); p=0.010 
 924 
 925 
S6 Table: SAEs and medication use by arm in the last 3 months 926 
SAE/psychotropic 
medication 
EUC  
number of SAEs (No. 
of participants) 
HAP+EUC 
Number of SAEs   (No. 
of participants) 
p-value 
SAEs  
Total SAEs  29 (34) 17 (18) p=0.12 
Death 2 (2) 0 (0) p=0.49 
Suicide attempt 1 (1) 1 (1) p=1.00 
Unplanned hospitalisation 26 (31) 18 (17) p=0.26 
Psychotropic medication No. of participants No. of participants  
Total psychotropic 
medication use 
11  7  p=0.47 
 927 
 928 
 929 
 930 
 931 
 932 
 933 
 934 
 935 
 936 
 937 
 938 
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S7 Table.  Mediation results examining patient-reported activation levels at 3-months 939 
on 12-month depression outcomes. 940 
Assessment point BA score (imputed 
data) 
Model Regression Result Bootstrap 95% CI 
 EUC 
(n=248) 
HAP+EUC 
(n=245) 
 Β* SE  
3 months  
mean (SD) 
9.81 
(4.31) 
12.01 
(4.71) 
c’ (HAP+EUC 
à BDI-II at 
12-months) 
-4.46*** 0.79 (-6.01, -2.91) 
12 months 10.02 
(4.64) 
11.00 
(4.49) 
a’ (HAP+EUC 
à activation at 
3-months) 
2.23*** 0.23 (1.77, 2.68) 
 b’ (activation 
at 3-months à 
BDI-II at 12 
months) 
-1.17*** 0.09 -1.35, -1.00) 
a x b -2.62*** 0.33 (-3.28, -1.97) 
 941 
Note: *Beta estimates are unstandardized. Multiple linear regression models controlled for baseline 942 
PHQ-9 scores, participant age, and PHC).  *p<0.05.  **p<0.01.  ***p<0.001 943 
c’ total effect; a x b: indirect effect 944 
 945 
S8 Table: Mean costs (2015 International Dollars) and QALYs gained per 946 
person over 12 months  947 
Type of Cost 
HAP+EUC 
arm 
(n=245) 
EUC arm 
(n=248) 
Mean Difference  
(95% CI) 
p-
value 
HAP intervention costs 
HAP Intervention (SE) 65.66 (3.48) 0 (0) 65.66 (58.80, 72.52) 0.000 
Health Service Utilisation 
PHC Doctor 
Consultations (SE) 51.64 (3.86) 58.77 (6.23) -7.13 (-21.54, 7.28) 0.331 
Hospital Doctor 
Consultations (SE) 84.06 (14.51) 116.96 (47.55) -32.90 (-130.75, 64.95) 0.509 
Hospital Admissions 
(SE) 19.92 (5.32) 39.08 (9.12) -19.16 (-39.92, 1.60) 0.070 
Laboratory Tests (SE) 23.91 (2.99) 39.08 (6.55) -15.16 (-29.32, -1.01) 0.036 
Medicines (SE) 24.62 (2.91) 34.39 (5.07) -9.77 (-21.27, 1.73) 0.096 
Total Health Service 
Utilisation Costs (SE) 204.15 (19.56) 288.27 (50.85) -84.12 (-191.32, 23.07) 0.124 
Total Health System Costs 
Total Health System 
Costs (SE) 269.81 (19.53) 288.27 (50.85) -18.47- (-125.64, 88.71) 0.735 
Productivity Costs     
Time costs to service 
users and families 
(SE) 164.70 (12.89) 154.89 (12.77) 9.81 (-25.83, 45.46) 0.589 
Productivity losses 
(SE) 344.95 (24.85) 491.22 (26.80) 
-146.28 (-218.08, -
74.47) 0.000 
 46 
Total Societal Costs       
 Societal perspective 
(SE) 779.46 (40.84) 934.39 (64.81) -154.93 (-305.51, -4.35) 0.044 
QALYs 
QALYs gained (SE) 0.848 (0.005) 0.837 (0.004) 0.011 (0.006, -0.002) 0.092 
 948 
 949 
 950 
 951 
 952 
 47 
 953 
 954 
 955 
 
S2 Figure: Cost effectiveness planes: HAP plus EUC compared to EUC per remission achieved 
A (Health System Perspective)       B (Societal Perspective) 
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